126 related articles for article (PubMed ID: 20452098)
1. [Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results].
Cornut PL; Poli M; Feldman A; El Chehab H; Swalduz B; Burillon C; Denis P
J Fr Ophtalmol; 2010 May; 33(5):327-33. PubMed ID: 20452098
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up.
Lorenzo D; Arias L; Alcubierre R; Pujol O; Caminal JM; Rubio M; CatalĂ J; Garcia-Bru P; Arruga J
Ophthalmologica; 2011; 226(3):103-9. PubMed ID: 21720153
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks.
Mimoun G; Tilleul J; Leys A; Coscas G; Soubrane G; Souied EH
Am J Ophthalmol; 2010 Nov; 150(5):692-700.e1. PubMed ID: 20719301
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.
Silva RM; Ruiz-Moreno JM; Rosa P; Carneiro A; Nascimento J; Rito LF; Cachulo ML; Carvalheira F; Murta JN
Retina; 2010 Mar; 30(3):407-12. PubMed ID: 20094007
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab treatment of macular choroidal neovascularization secondary to angioid streaks: one-year results of a prospective study.
Ladas ID; Kotsolis AI; Ladas DS; Niskopoulou M; Georgalas I; Papakonstantinou D; Rouvas AA
Retina; 2010 Sep; 30(8):1185-9. PubMed ID: 20539257
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.
Yamamoto I; Rogers AH; Reichel E; Yates PA; Duker JS
Br J Ophthalmol; 2007 Feb; 91(2):157-60. PubMed ID: 16870653
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
[TBL] [Abstract][Full Text] [Related]
10. [Intravitreal injections of ranibizumab in treatment of large peripapillary choroidal neovascularization].
Nochez Y; Le Lez ML; Pisella PJ
J Fr Ophtalmol; 2009 Jan; 32(1):25-31. PubMed ID: 19515310
[TBL] [Abstract][Full Text] [Related]
11. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.
Konstantinidis L; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Mar; 247(3):311-8. PubMed ID: 19043731
[TBL] [Abstract][Full Text] [Related]
13. [Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularization--cases report].
Figurska M; Stankiewicz A
Klin Oczna; 2008; 110(10-12):387-91. PubMed ID: 19195173
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
15. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients.
Yang X; Dai H
Chin Med J (Engl); 2014; 127(16):2906-10. PubMed ID: 25131225
[TBL] [Abstract][Full Text] [Related]
18. [The therapeutic effects of photodynamic therapy on choroidal neovascularization of pathologic myopia].
Zhang MX; Yan M; Zhang JJ; Tang J; Wei CY; Meng D
Zhonghua Yan Ke Za Zhi; 2007 Jul; 43(7):638-41. PubMed ID: 17897555
[TBL] [Abstract][Full Text] [Related]
19. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
Varano M; Tedeschi M; Oddone F; Perillo L; Coppè AM; Parravano M
Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]